https://www.barostim.com/surgical-experience-and-long-term-results-of-barore%ef%ac%82ex-activation-therapy-for-heart-failure-with-reduced-ejection-fraction/ 2022-04-08T13:22:16+00:00 https://www.barostim.com/barostim-therapy-for-heart-failure-patients/ 2022-05-03T14:03:43+00:00 https://www.barostim.com/bat-in-hf-12-month-data/ 2022-05-03T14:13:24+00:00 https://www.barostim.com/bat-in-hf-phase-i-clinical-study-results/ 2022-05-03T14:13:41+00:00 https://www.barostim.com/beat-hf-presented-at-esc-hf/ 2022-05-03T14:19:35+00:00 https://www.barostim.com/cvrx-inc-appoints-nadim-yared-president-and-ceo/ 2022-05-03T14:34:21+00:00 https://www.barostim.com/cvrx-raises-50-million-in-new-equity-financing/ 2022-05-03T14:36:10+00:00 https://www.barostim.com/barostim-for-hfpef/ 2022-05-03T14:58:41+00:00 https://www.barostim.com/barostim-neo-heart-failure-treatment-results-in-high-responder-and-super-responder-rates/ 2022-05-03T14:59:46+00:00 https://www.barostim.com/barostim-neo-reduces-heart-failure-symptoms-for-patients-with-atrial-fibrillation-and-or-lvef-25/ 2022-05-03T15:00:10+00:00 https://www.barostim.com/barostim-therapy-in-patients-with-heart-failure-with-a-reduced-ejection-fraction-impact-in-women/ 2022-05-03T15:01:48+00:00 https://www.barostim.com/barostim-therapy-projected-to-be-cost-effective-in-treating-resistant-hypertension/ 2022-05-03T15:02:33+00:00 https://www.barostim.com/beat-hf-jacc-publication/ 2022-05-03T15:02:54+00:00 https://www.barostim.com/cardiology-news-women-thrive-on-baroreflex-activation-for-heart-failure/ 2022-05-03T15:03:13+00:00 https://www.barostim.com/cvrx-announces-expedited-access-pathway-designation-by-fda/ 2022-05-03T15:03:31+00:00 https://www.barostim.com/cvrx-announces-publication-of-beat-hf-clinical-study-results-in-the-journal-of-the-american-college-of-cardiology/ 2022-05-03T15:04:59+00:00 https://www.barostim.com/cvrx-barostim-therapy-for-heart-failure-clinical-trial-results-presented-in-a-featured-clinical-research-session-of-the-american-college-of-cardiology-annual-conference/ 2022-05-03T15:05:19+00:00 https://www.barostim.com/cvrx-barostim-therapy-for-heart-failure-clinical-trial-results-presented-in-the-late-breaking-clinical-session-of-the-esc-heart-failure-2015-annual-conference/ 2022-05-03T15:05:37+00:00 https://www.barostim.com/cvrx-barostim-therapy-for-heart-failure-clinical-trial-results-presented-in-the-late-breaking-clinical-trial-session-of-the-heart-rhythm-society-2015-annual-conference/ 2022-05-03T15:07:57+00:00 https://www.barostim.com/cvrx-completes-enrollment-of-the-beat-hf-phase-iii-randomized-clinical-trial-continues-to-collect-morbidity-and-mortality-outcomes/ 2022-05-03T15:09:08+00:00 https://www.barostim.com/cvrx-granted-ce-marking-of-the-barostim-neo-system-for-conditional-mri-compatibility/ 2022-05-03T15:09:24+00:00 https://www.barostim.com/cvrx-granted-humanitarian-device-exemption-approval-from-fda-for-barostim-neo-legacy-hypertension-therapy-device/ 2022-05-03T15:09:43+00:00 https://www.barostim.com/cvrx-inc-receives-ce-mark-approval-for-rheos-baroreflex-hypertension-therapy-system/ 2022-05-03T15:10:16+00:00 https://www.barostim.com/cvrx-receives-ce-mark-approval-and-introduces-new-implantable-device-for-hypertension-the-barostim-neo/ 2022-05-03T15:10:45+00:00 https://www.barostim.com/cvrx-receives-ce-mark-approval-of-the-barostim-neo-system-for-the-treatment-of-heart-failure/ 2022-05-03T15:11:29+00:00 https://www.barostim.com/editorial-accompanying-the-jacc-publication-of-beat-hf-clinical-study-results/ 2022-05-03T15:11:48+00:00 https://www.barostim.com/response-by-gender/ 2022-05-03T15:12:06+00:00 https://www.barostim.com/response-by-sex-in-patient-centered-outcomes-with-baroreflex-activation-therapy-in-systolic-heart-failure/ 2022-05-03T15:12:24+00:00 https://www.barostim.com/wp-content/uploads/2021/06/jacc-featured-img.png https://www.barostim.com/hope4hf-phase-ii-clinical-study-results/ 2022-05-05T18:35:28+00:00 https://www.barostim.com/cvrx-announces-first-clinical-procedure-with-a-new-ultrasound-guided-implant-approach-the-latest-advancement-in-barostim-for-the-treatment-of-heart-failure-symptoms/ 2022-05-26T16:03:03+00:00 https://www.barostim.com/wp-content/uploads/2021/06/press-release-1.png https://www.barostim.com/cmsntap/ 2022-09-08T14:50:44+00:00 https://www.barostim.com/cvrx-launches-a-new-barostim-programmer/ 2022-09-08T14:52:18+00:00 https://www.barostim.com/wp-content/uploads/2022/07/CVRX-CircleImage-3.png https://www.barostim.com/see-the-poster-here-quality-of-life-response-to-barostim-therapy/ 2022-09-08T14:55:54+00:00 https://www.barostim.com/cms-approval-for-transitional-pass-through-payment-status/ 2022-09-08T14:59:07+00:00 https://www.barostim.com/wp-content/uploads/2021/06/press-release-1.png https://www.barostim.com/cost-impact-analysis-of-baroreflex-activation-therapy-in-chronic-heart-failure-patients-in-the-united-states/ 2022-09-08T14:59:27+00:00 https://www.barostim.com/wp-content/uploads/2021/04/cost-impact-img.png https://www.barostim.com/cvrx-announces-new-cfo-and-acceleration-of-barostim-therapy-commercialization-efforts/ 2022-09-08T14:59:46+00:00 https://www.barostim.com/wp-content/uploads/2020/11/press-release-3.png https://www.barostim.com/cvrx-appoints-new-chief-marketing-officer-and-vice-president-of-european-sales-and-marketing/ 2022-09-08T15:00:01+00:00 https://www.barostim.com/wp-content/uploads/2021/01/press-release-2.png https://www.barostim.com/cvrx-receives-mr-conditional-labeling-approval-for-its-barostim-heart-failure-system/ 2022-09-08T15:00:18+00:00 https://www.barostim.com/wp-content/uploads/2021/06/press-release-1.png https://www.barostim.com/fda-approval/ 2022-09-08T15:00:35+00:00 https://www.barostim.com/see-the-poster-here-symptomatic-endpoint-responder-rates-to-barostim-therapy/ 2022-09-08T15:00:51+00:00 https://www.barostim.com/cvrx-launches-new-barostim-neo2-implantable-pulse-generator/ 2022-11-21T21:09:28+00:00 https://www.barostim.com/barostim-neo-reduces-heart-failure-symptoms-for-patients-with-or-without-atrial-fibrillation/ 2024-01-17T20:03:51+00:00 https://www.barostim.com/barostim-neo-reduces-the-institutional-cost-burden-of-heart-failure/ 2024-01-17T20:04:38+00:00 https://www.barostim.com/barostim-neo-shows-a-reduction-in-serious-cardiovascular-events/ 2024-01-17T20:08:39+00:00 https://www.barostim.com/allina-healths-abbott-northwestern-hospital-is-first-in-minnesota-to-implant-barostim-therapy-to-improve-symptoms-of-heart-failure/ 2024-03-19T13:59:20+00:00 https://www.barostim.com/cvrx-announces-availability-of-additional-data-supporting-long-term-benefits-of-barostim/ 2024-04-29T14:16:21+00:00 https://www.barostim.com/barostim-neo-associated-with-very-high-responder-rates-in-women/ 2024-05-17T20:04:06+00:00